Another one of the studies described involved downregulating CD133 expression in HepG2-CD133+ cells using lentivirus-mediated shRNA, followed by an analysis of the effects of CD133 on the modulation of stemness properties and chemoradiosensitivity in liver cancer stem cells (LCSCs) [202]. This evidence concerns the gene PROM1 and liver cancer.